The medical consortium bargained the purchase of large varieties, and the original research drug selected can obtain more than 80% of the purchase volume!

Medical Network, March 18, on March 17, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Announcement on Centralized Negotiated Procurement of Drugs from the "Xinhua-Chongming" Regional Medical Consortium (the first batch in 2021)".
15 drugs, including pioglitazone, nifedipine and pravastatin, started the centralized drug purchase by bargaining, involving three categories of systemic anti-infectives, gastrointestinal and metabolic drugs, and cardiovascular drugs
.
It is worth noting that the procurement plan puts forward special requirements: each medical institution shall formulate a procurement plan for the selected drugs according to not less than 60% of the quantity purchased in the previous year and not less than 60% of the purchase quantity of the same product in this year .
Among them, the selected drugs that passed the consistency evaluation were not less than 70% of the purchase quantity of the same product this year, and the selected drugs of the original research drug were not less than 80% of the purchase quantity of the same product this year
.
Or it aims to attract and encourage pharmaceutical companies to participate in this centralized bargaining by giving a large enough market share
.

Bargaining competition
for15 major clinical varieties.
For the 15 varieties included in the first batch of centralized bargaining purchases of drugs, Shanghai explained that they are based on the large clinical use of drugs, high purchase amount, mature clinical use, sufficient market competition, and outstanding mass gains.
As well as the principles of drugs with abnormal prices on the Sunshine platform (such as those whose prices are significantly higher than other brands of the same variety or whose prices have risen significantly), some of the varieties that are being purchased and used by medical institutions in Chongming District in the Medical Federation were selected and determined
.
Judging from the basis for the calculation of the agreed purchase volume in the first year, the commonly used antihypertensive calcium channel blocker amlodipine aspartate is undoubtedly the highlight of this centralized bargaining, with the purchase volume of 12.
02 million tablets ranking first
.
According to data from Menet.
com, in 2019, the total sales of amlodipine in Chinese public medical institutions and physical pharmacies in cities in China exceeded 8 billion yuan.

.
However, due to the inclusion of amlodipine besylate in the first batch of national centralized procurements, the terminal sales of the entire category of amlodipine in China's public medical institutions have declined in the past two years, but the terminal sales of physical pharmacies in Chinese cities have continued to rise
.
As for this time of amlodipine aspartate, only Jianfeng Pharmaceutical currently holds the approval for the product to be marketed
.
How the bargaining situation remains to be seen .
The purchase of another antihypertensive drug, angiotensin II antagonist, Losartan Potassium Hydrochlorothiazide, is second only to Amlodipine Aspartate, which is also a highlight of this centralized bargaining
.
According to data from Mi Nei.
com, in 2019, in the cardiovascular system drug market of China's public medical institutions and China's urban retail pharmacies, the total market size of drugs that act on the renin-angiotensin system has risen to more than 30 billion yuan and succeeded.
Beyond blood lipid regulators has become the largest sub-category
.
The total sales of Losartan Potassium Hydrochlorothiazide in 2019 is also a large variety of more than 1 billion yuan.
Currently, the original research drug company Merck & Co.
leads the market, Shandong Xinyi, Suzhou Dongrui, Beijing Fuyuan, Lepu Pharmaceutical, etc.
Domestically-produced enterprises will follow closely behind, and may become a group with fierce price competition
.

　　The selection rule is not the only low price is based
on the industry’s attention to the selection rule.
Shanghai proposes to reduce falsely high drug prices on the basis of ensuring quality and supply, but avoid the practice of taking only low prices, and use comprehensive clinical drug evaluation, medication and diagnosis and treatment.
Guidelines, third-party evaluations, etc.
comprehensively determine the selected drugs with high cost performance
.
The specific approach is that Shanghai will set the score weights of 60% and 25% for the three dimensions of the third-party evaluation of the DRS drugs of the China Pharmaceutical Industry Information Center, the proportion of the city’s historical purchases, and the coverage of the city’s medical institutions.
, 15%, a comprehensive evaluation with a total score of 100 points
.
Sort the comprehensive evaluation scores of all the declared drugs, and determine the finalists according to the number of finalists (see the table below for details), and the same comprehensive evaluation scores will be finalized at the same time
.
The price reduction is still an important factor in the final selection.
According to the selection rules, Shanghai will determine the selected drugs according to the comprehensive price score from high to low, and the comprehensive price score is composed of the price reduction score and the quotation score.
The proportions are 80% and 20% respectively
.
However, Shanghai has also made an agreement that, after reviewing experts’ reviews, relevant shortlisted companies can be organized to negotiate prices for drugs that are not sufficiently competitive
.
However, if the competition for the secondary quotation is still insufficient, the selected drug will not be confirmed
.
In addition, the implementation cycle of the results of this centralized bargaining procurement is tentatively set for 2 years, and the products that are exclusively sold in Shanghai are tentatively set for 1 year
.
Or for the purpose of attracting and encouraging pharmaceutical companies to actively participate in this centralized bargaining, Shanghai has set a rigid indicator for the purchase volume of selected drugs
.
On the basis of formulating a procurement plan for the selected drugs in accordance with not less than 60% of the quantity purchased in the previous year and not less than 60% of the quantity purchased from the same product in this year, Shanghai also requires that the consistency evaluation be passed.
The selected drugs in this year are no less than 70% of the purchase quantity of the same product regulations, while the selected drugs of the original research drug are not less than 80% of the purchase quantity of the same product regulations this year
.
Whether Shanghai's new bargaining regulations can attract the in-depth participation of pharmaceutical companies, especially multinational pharmaceutical companies, remains to be announced
.

　　Constructing a multi-party
drug centralized procurement pattern The launch of the first batch of regional medical consortia drug centralized bargaining procurement is actually the implementation of Shanghai's policy to build a multi-party drug centralized procurement structure
.
In July 2020, the Shanghai Municipal Medical Insurance Bureau issued the "Trial Opinions on Building a Multi-Party Linked Drug Centralized Purchase Pattern to Encourage and Promote the City’s Drug Centralized Negotiation Procurement" (Shanghai Medical Insurance Price [2020] No.
77) to encourage Shanghai Public medical institutions can explore the centralized bargaining procurement of medicines in the form of medical consortia, single units, or voluntary formation of purchasing alliances
.
According to Shanghai’s deployment, centralized drug procurement through bargaining is included in the overall framework of the city’s medical recruitment and procurement system as an important part of the drug supply security system
.
Shanghai intends to use centralized drug purchases through bargaining to give full play to the advantages of bulk purchases, as an effective supplement to the country and the city's drug purchases, enhance the bargaining scale effect of other drugs purchased on the Internet, and jointly promote the formation of a market-led, multi-party linkage The drug price formation mechanism realizes the overall effect of reducing drug prices, reducing the burden on patients, and saving medical costs
.
It is worth noting that, in order to amplify the procurement effect of centralized bargaining, Shanghai also stated in its opinions that it will explore the centralized bargaining procurement of medical devices in a timely manner based on the evaluation and summary of the effectiveness of centralized drug procurement
.
From the perspective of the industry, under the guidance of the “Opinions on Promoting the Normalization and Institutionalization of Centralized and Volume Procurement of Drugs” by the General Office of the State Council, the volumetric procurement of drugs will formally become normalized, and the exploration of local drug procurement will also be further accelerated
.